Webcast must be viewed in its entirety to claim credit.
This activity is provided by the Chronic Liver Disease Foundation.
This program is supported by an educational grant from AbbVie.
This educational program is targeted at physicians and other healthcare providers who specialize in the management of patients with substance use disorders.
Upon completion of this activity, the participants should be better able to:
Examine data on the prevalence and transmission of the hepatitis C virus (HCV) in the substance use disorder (SUD) population.
Discuss strategies to reduce HCV reinfections
Describe various HCV linkage to care models, emphasizing that "one size does not fit all"
Analyze the need to prioritize HCV treatment in PWID
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 0.5AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 0.5 contact hours may be earned for successful completion of this activity.
Disclosure of Conflicts of Interest:
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc., all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF) have no relationships to disclose.
The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Presenter Disclosure Statement:
Robert Wong, MD
Dr. Robert Wong has received research support from Gilead, AbbVie and the AASLD Foundation. Also, Dr. Wong served on the speaker bureaus' of Gilead, Bayer and Salix and as a consultant for Gilead.